OBJECTIVES: To examine the effect of certolizumab pegol (CZP) on workplace and household productivity up to 48 weeks (wks), in patients (pts) with active psoriatic arthritis (PsA). METHODS: The ongoing RAPID-PsA trial (NCT01087788) is double-blind and placebo-controlled to Wk24 and dose-blind to Wk48. Pts had active PsA and had failed ≥1 DMARD. Pts originally randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in dose-blind phase; placebo pts entering dose-blind phase were re-randomized to CZP loading dose, followed by CZP 200mg Q2W or CZP 400mg Q4W. This publication reports data for pts in the randomised set (RS) originally randomized to CZP. The validated arthritis-specific Work Productivity Survey (WPS), administered Q4W from baseline (BL), assessed the impact of PsA on workplace and household productivity. WPS responses (LOCF imputation) in both CZP groups are summarized descriptively over 48 wks. RESULTS: 409 pts were randomized, of which 273 were assigned to CZP 200mg Q2W or CZP 400mg Q4W. 87% of patients randomized to CZP completed to Wk48. 60.1% and 61.5% were employed at BL in the CZP 200mg Q2W and CZP 400mg Q4W groups, respectively. By Wk48, employed CZP pts reported reduced workplace absenteeism (Wk48: mean 0.1 and 0.6 days missed/month for CZP 200mg Q2W and 400mg Q4W, respectively vs BL: mean 2.0 and 1.6 days/month) and presenteeism (Wk48: mean 0.8 and 1.9 days with reduced productivity/month vs BL: mean 5.2 and 5.1 days/month). CZP groups also reported improvements in household productivity and increased participation in social/leisure activities up to Wk48. CONCLUSIONS: The initial improvements with CZP in workplace and household productivity, and participation in social/leisure activities observed over 24 wks were maintained over 48 wks in PsA pts.